Trending Now
ProQR Therapeutics N.V. (NASDAQ: PRQR) Announce Seporfarse Study in LCA10 Treatment...
ProQR Therapeutics N.V. (NASDAQ: PRQR) has revealed that its viral Phase 2/3 Illuminate study of sepofarsen for CEP290-Mediated Leber congenital amaurosis 10 (LCA10) treatment...
Reason why ReShape Lifesciences Stock (RSLS) is surging
ReShape Lifesciences Stock More than doubled and last traded at $17.04+10.74 (+170.48%). However, the stock lost quite a bit of steam after...
C3.ai Inc (NYSE:AI) gains over 30% in 3 days on strength...
ChatGPT has taken the world by storm and Buzzfeed (BZFD) got the party started with a ChatGPT PR last week which sent...
Popular News
AlloVir’s (NASDAQ:ALVR) Receives IND Clearance For ALVR106 In Respiratory Disease and...
The US FDA has cleared AlloVir’s (NASDAQ:ALVR) Investigational New Drug (IND) application for ALVR106. ALVR106 is the company's off-the-shelf, allogeneic virus specific...
MAKE IT MODERN
LATEST REVIEWS
Vaxart Inc. (NASDAQ:VXRT) Picks Its Lead Oral Coronavirus Vaccine Candidate And...
Vaxart Inc. (NASDAQ:VXRT) has announced that it has chosen its lead coronavirus vaccine candidate as well as contracted KindredBio to produce the vaccine in...
MAKE IT MODERN
PERFORMANCE TRAINING
Seelos Therapeutics Inc. (NASDAQ: SEEL) Announce License Agreement With iX Biopharma For Wafermine Commercialization
Seelos Therapeutics Inc. (NASDAQ: SEEL) and iX BioPharma have announced a license agreement pursuant to which iX Biopharma will license its lead drug candidate...
Sarepta Therapeutics Inc. (NASDAQ: SRPT) Reports Preliminary Q3 2021 Results And Data Analyse From...
Sarepta Therapeutics Inc. (NASDAQ: SRPT) has announced its preliminary Q3 2021 financial results. The company expects net product revenues of $166.9 million relative to...
CytomX Therapeutics Inc (NASDAQ: CTMX) Announces Phase 2 Findings For Praluzatamab Ravtansine in Breast...
CytomX Therapeutics Inc (NASDAQ: CTMX) has announced that its second phase study of praluzatamab rvtansine in individuals with hormone receptor-positive (HR+)/human epidermal growth factor...
Investing in Emerging Ad Tech Opportunities (PUBM, CRTO, CMGR, MGNI)
The Ad industry is rapidly evolving before our eyes. But evolution is nothing new to this space. It has always been in...
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) Expects Full Year 2021 Revenue of $29.7 Million For...
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) has announced interim Q4 and full-year 2021 net revenue forecasts for its first in class oral XPO1 inhibitor, XPOVIO,...
MAKE IT MODERN
[/tdc_zone]